Clinical Trials

GastrointestinalHead & Neck

7 enrolled 14 charts

Pyridoxine-dependent epilepsy, Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Esophageal Neoplasms, Head and Neck Neoplasms, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms

NCT03040999 2026-02-04

KEYNOTE-412

804 enrolled 20 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05814666 2026-01-30

PEMDA-HN

69 enrolled 21 charts

Phase 1/2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT03474497 2026-01-29

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

18 enrolled 13 charts

DermatologicGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT03468218 2026-01-23

Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell Cancer

Phase 2 Active not recruiting

36 enrolled 11 charts

BreastGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck

NCT05070247 2026-01-22

A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Terminated

61 enrolled 29 charts

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Mesothelioma, Nasopharyngeal Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms

NCT02819752 2026-01-21

PEACH

Phase 1 Terminated

3 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04428151 2025-12-04

LEAP-009

408 enrolled 17 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT03358472 2025-12-03

Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)

89 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04454489 2025-11-19

Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition

21 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck

NCT04854499 2025-11-19

ELEVATE HNSCC

193 enrolled 27 charts

Squamous Cell Carcinoma of Head and Neck

NCT02882282 2025-10-23

Pembrolizumab in Treating Patients With High Risk Oral Intraepithelial Neoplasia

15 enrolled 8 charts

Mouth Neoplasms

NCT03049618 2025-10-22

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

42 enrolled 40 charts

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT06046482 2025-10-22

Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma

4 enrolled 11 charts

Squamous Cell Carcinoma of Head and Neck

NCT02586207 2025-10-07

Pembrolizumab in Combination With CRT for LA-SCCHN

59 enrolled 9 charts

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Diseases, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT05061420 2025-09-22

A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)

59 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck

NCT05323656 2025-09-02

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

55 enrolled 32 charts

Squamous Cell Carcinoma of Head and Neck

NCT02973997 2025-08-29

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Phase 3 Active not recruiting

57 enrolled 14 charts

EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

NCT03765918 2025-08-20

MK-3475-689

714 enrolled 90 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT02475213 2025-08-11

Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer

DermatologicGenitourinaryHead & NeckThoracic

146 enrolled 38 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Melanoma

NCT02903914 2025-08-05

Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors

GastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

260 enrolled 52 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms

NCT02892201 2025-07-29

Pembrolizumab in HNSCC With Residual Disease After Radiation

9 enrolled 15 charts

Squamous Cell Carcinoma of Head and Neck

NCT02358031 2025-07-18

MK-3475-048

882 enrolled 50 charts 1 FDA

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT04489888 2025-06-19

MK-3475-B10

Phase 4 Completed

101 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck

NCT04555837 2025-05-20

Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer

24 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT04633278 2025-05-11

CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

24 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Head and Neck Neoplasms

NCT04199104 2025-04-23

A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010)

511 enrolled 20 charts

Squamous Cell Carcinoma of Head and Neck

NCT04032704 2025-03-10

A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

205 enrolled 54 charts

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Carcinoma, Non-Small-Cell Lung, Melanoma, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT02289209 2025-03-06

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

48 enrolled 18 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Head and Neck Neoplasms

NCT03058289 2025-02-27

IT-01

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

111 enrolled 21 charts

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT03085719 2025-02-25

Targeting PD-1 Therapy Resistance With Focused High or High and Low Dose Radiation in SCCHN

Phase 2 Active not recruiting

18 enrolled 22 charts

Head and Neck Neoplasms

NCT03625323 2024-12-18

TACTI-002

187 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck

NCT02538510 2024-11-26

Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

50 enrolled 13 charts

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Salivary Gland Neoplasms

NCT03769467 2024-11-14

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Phase 1/2 Terminated

12 enrolled 8 charts

Nasopharyngeal Carcinoma, Carcinoma, Head and Neck Neoplasms, Stomatognathic Diseases, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Nose Neoplasms, Otorhinolaryngologic Diseases, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Pharyngeal Neoplasms, Epstein-Barr Virus Infections

NCT02609503 2024-11-05

Pembrolizumab + Radiation for Locally Adv SCC of the Head and Neck (SCCHN) Not Eligible Cisplatin

29 enrolled 27 charts

Head and Neck Neoplasms

NCT04428333 2024-10-09

INDUCE-4

Phase 3 Terminated

117 enrolled 33 charts

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02641093 2024-08-29

Phase II Trial of Adjuvant Cisplatin and Radiation With Pembrolizumab in Resected Head and Neck Squamous Cell Carcinoma

96 enrolled 12 charts

Head and Neck Neoplasms

NCT02777385 2024-08-01

Pembrolizumab in Combination With Cisplatin and Intensity Modulated Radiotherapy (IMRT) in Head and Neck Cancer

80 enrolled 25 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

NCT04128696 2024-07-10

INDUCE-3

Phase 3 Terminated

315 enrolled 31 charts

Head and Neck Neoplasms, Neoplasms

NCT04936841 2024-04-04

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

5 enrolled 17 charts

Head and Neck Neoplasms

NCT02718820 2024-01-09

Pembrolizumab Plus Docetaxel for the Treatment of Recurrent or Metastatic Head and Neck Cancer

22 enrolled 10 charts

Head and Neck Carcinoma

NCT03229278 2023-12-06

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma